Entrectinib

361 interactions 392 cited references

Also sold as: Rozlytrek Rozlytrek®

About Entrectinib

Entrectinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat certain types of solid tumors in adults and children 12 years of age and older that cannot be treated by surgery or that has spread to other parts of the body… Read the full Entrectinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Piperaquine Posaconazole Saquinavir Ketoconazole Topical Pimozide

29 Contraindicated 325 Major 7 Moderate

All (361) Contraindicated (29) Major (325) Moderate (7)

Major

Entrectinib Pimavanserin Nuplazid An increased risk of QT interval prolongation Details Entrectinib Pipamperone An increased risk of QT interval prolongation Details Entrectinib Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Entrectinib Pitolisant Wakix An increased risk of QT interval prolongation Details Entrectinib Ponesimod Ponvory An increased risk of QT interval prolongation Details Entrectinib Primidone Mysoline An increased risk of QT interval prolongation, reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Probucol An increased risk of QT interval prolongation Details Entrectinib Procainamide Procan® An increased risk of QT interval prolongation Details Entrectinib Prochlorperazine An increased risk of QT interval prolongation Details Entrectinib Promethazine Phenadoz An increased risk of QT interval prolongation Details Entrectinib Propafenone Rythmol An increased risk of QT interval prolongation Details Entrectinib Protriptyline An increased risk of QT interval prolongation Details Entrectinib Quetiapine Seroquel An increased risk of QT interval prolongation Details Entrectinib Quinidine Cardioquin® An increased risk of QT interval prolongation Details Entrectinib Quinine An increased risk of QT interval prolongation Details Entrectinib Quizartinib Vanflyta An increased risk of QT interval prolongation Details Entrectinib Ranolazine Aspruzyo Increased ranolazine exposure, increased entrectinib exposure and an increased risk of QT interval prolongation Details Entrectinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Entrectinib Repotrectinib Augtyro Increased repotrectinib exposure, an increased risk of repotrectinib-related adverse effects, reduced CYP3A4 substrates exposure a... Details Entrectinib Revumenib Revuforj An increased risk of QT interval prolongation Details Entrectinib Ribociclib Kisqali Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Rifabutin Mycobutin Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Rifampin Rifadin Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Rifapentine Priftin Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Rilpivirine Edurant An increased risk of QT interval prolongation and torsade de pointes Details Entrectinib Risperidone Perseris An increased risk of QT interval prolongation Details Entrectinib Ritlecitinib Litfulo Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Ritonavir Norvir Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Roflumilast Daliresp Increased roflumilast exposure and an increased risk of roflumilast-related adverse events Details Entrectinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Entrectinib Schisandra Sphenanthera Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Selpercatinib Retevmo Increased substrate exposure, an increased risk of adverse reaction and an increased risk of QT interval prolongation Details Entrectinib Sertindole An increased risk of QT interval prolongation Details Entrectinib Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Entrectinib Sevoflurane Petrem An increased risk of QT interval prolongation Details Entrectinib Siponimod Mayzent An increased risk of QT interval prolongation Details Entrectinib Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation Details Entrectinib Sodium Phosphate, Dibasic An increased risk of QT interval prolongation Details Entrectinib Sodium Phosphate, Monobasic An increased risk of QT interval prolongation Details Entrectinib Solifenacin Vesicare An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.